Senior Scientist, Quantitative Modeling & PK

CSL; Opfikon; On-site; CHF 160,000 - 210,000; Full time

Job summary

CSL Behring seeks a Senior Scientist in Quantitative Modeling & PK to support non-clinical drug development from candidate selection to first-in-human dose prediction. You will combine modeling with PK, pharmacology, and non-clinical development knowledge to inform critical decisions.

You will design informative studies, integrate diverse datasets, develop predictive models, and translate quantitative insights into actionable development recommendations within a cross-functional team.

Qualifications

• Ph.D., M.Sc., or equivalent degree in Pharmacometrics, Pharmaceutical Sciences, Pharmacology, Biomedical Engineering, Applied Mathematics, Systems Biology, or a related discipline.
• Minimum 3 years of experience applying modeling and simulation approaches to support non-clinical drug development.
• Strong quantitative modeling skills, with experience in PK/PD, PBPK, QSP, and/or other mechanistic modeling approaches.

Responsibilities

• Apply fit-for-purpose quantitative modeling approaches to address non-clinical development questions (candidate selection, study design, FIH dose).
• Develop and apply modeling methods including exposure-response, PK-target binding, empirical and mechanistic PK/PD, PBPK, QSP.
• Contribute to design, analysis, and interpretation of non-clinical PK, PK/PD, and mechanistic studies to reduce risk.
• Perform non-compartmental analysis (NCA) of PK and TK data and prepare reports for regulatory submissions.
• Communicate quantitative insights clearly to technical and non-technical audiences.
• Contribute to regulatory submission documents with quantitative analyses and justifications.
• Collaborate with cross-functional teams, especially non-clinical pharmacology, toxicology, translational research, and clinical pharmacology.

Skills

Quantitative modeling

PK/PD modeling

PBPK modeling

QSP modeling

Data integration

Education

Ph.D. in Pharmacometrics

M.Sc. in Pharmaceutical Sciences

Related discipline degree

Tools

Monolix

Simulx

NONMEM

R

MATLAB

Phoenix WinNonlin

Job description

The Senior Scientist, Quantitative Modeling & PK supports non-clinical drug development from candidate selection through first-in-human dose prediction by applying fit-for-purpose quantitative modeling approaches to inform key development decisions. Embedded within the Non-Clinical PK & Modeling group, the role combines quantitative modeling with a strong understanding of pharmacokinetics, pharmacology, and non-clinical development. The successful candidate will work closely with PK scientists and cross-functional project teams to design informative studies, integrate diverse datasets, develop predictive models, and translate quantitative insights into actionable development recommendations.

Main Responsibilities

• Apply fit-for-purpose quantitative modeling approaches to address key non-clinical development questions, including candidate selection, study design, and first-in-human dose prediction.
• Develop and apply a range of modeling methodologies, including exposure-response, PK-target binding, empirical and mechanistic PK/PD, PBPK, systems biology, and QSP models.
• Contribute to the design, analysis, and interpretation of non-clinical PK, PK/PD, and mechanistic studies to maximize decision-making value and reduce development risk.
• Perform non-compartmental analysis (NCA) of PK and TK data and prepare corresponding reports to support regulatory submissions.
• Communicate quantitative insights and recommendations clearly to both technical and non-technical audiences.
• Contribute to the preparation and review of regulatory submission documents, including quantitative analyses and scientific justifications.
• Collaborate closely with cross-functional project teams, in particular with non-clinical pharmacology, toxicology, translational research, and clinical pharmacology.

Qualifications and Experience Requirements

• Ph.D., M.Sc., or equivalent degree in Pharmacometrics, Pharmaceutical Sciences, Pharmacology, Biomedical Engineering, Applied Mathematics, Systems Biology, or a related discipline.
• Minimum 3 years of experience applying modeling and simulation approaches to support non-clinical drug development in a pharmaceutical, biotechnology, or CRO environment.
• Strong quantitative modeling skills, with experience in PK/PD, PBPK, QSP, and/or other mechanistic modeling approaches.
• Good understanding of PK, pharmacology, and non-clinical drug development, including experience supporting the design, analysis, and interpretation of preclinical PK and/or PK/PD studies.
• Experience using industry-standard modeling and data analysis tools such as Monolix, Simulx, NONMEM, R, MATLAB, Phoenix WinNonlin, or similar platforms.
• Strong communication and collaboration skills, with the ability to work effectively in cross-functional teams.
• Scientific curiosity and integrity, sound judgment, and the ability to work independently in a fast-paced development environment.
• Experience with multiple drug modalities and/or therapeutic areas is desirable.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.

To learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit and CSL Plasma at .